Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

The search for an HIV prevention vaccine news

Show

From To
The three big studies pushing at the frontiers of HIV prevention

These trials are being conducted under the auspices of the HIV Vaccine Trials Network. The network currently runs 49 clinical trial sites in nine countries with 18 ongoing trials, four of which are efficacy trials. Three trials are of particular interest as they have already been running since 2016 and are expected to close in late 2021.

Published
16 June 2019
From
The Conversation
Johnson & Johnson Announces Full Enrollment in Proof-of-Concept Efficacy Study of Janssen’s Investigational HIV Preventive Vaccine

Phase 2b efficacy study of mosaic-based vaccine successfully enrolls 2,600 women aged 18-35 across five southern African countries

Published
31 May 2019
From
Janssen press release
Will a vaccine crisis of confidence impact the global response to HIV?

Mitchell Warren of AVAC: "The implications of the anti-vaccination movement are enormous. Just as vaccines against some of the greatest global killers finally come within reach, fear and misinformation could diminish vital commitments to continued vaccine research, and important investments in vaccine education and delivery."

Published
20 May 2019
From
Science Speaks
Despite Uptick, Black and Latinx People Have Relatively Low Participation in HIV Vaccine Trials

Black and Latinx people historically have not willfully participated in clinical trials in high numbers. Medical mistrust of research and health care institutions has long been a problem for conducting biomedical research. So what's causing the racial disparities in research participation, and what are researchers doing about it?

Published
14 May 2019
From
The Body Pro
NIH Awards Will Advance Development of Vaccines for Sexually Transmitted Infections

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced awards to establish four Cooperative Research Centers (CRCs) focused on developing vaccines to prevent sexually transmitted infections (STIs). The grants, totaling $41.6 million over five years, will support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea and chlamydia. At the end of the program, each center is expected to identify at least one candidate vaccine ready for testing in clinical trials.

Published
10 May 2019
From
National Institute of Allergy and Infectious Diseases
Scientists Identify Factors That Make People Naturally Resistant to HIV

Studying key points on the HIV virus that are weak to immune system attacks could lead to new treatments or HIV vaccines.

Published
07 May 2019
From
Smithsonian
HIV vaccine science in Africa, for Africa

Africa is contributing far more than samples to scientific research. The continent’s scientists are actively engaged in developing and testing novel HIV vaccine candidates.

Published
03 May 2019
From
IAVI Report
HIV antibody VRC01LS safe prevention strategy for infants

Subcutaneous doses of a broadly neutralizing monoclonal antibody, known as VRC01LS, given at birth and 12 weeks were well-tolerated by HIV-exposed infants, according to the results of an open-label safety and pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections. Researchers are studying VRC01LS in combination with ART to prevent HIV infection in neonates.

Published
12 March 2019
From
Healio
CROI 2019: Thailand’s strides spanned HIV treatment, prevention and research

he first HIV vaccine trials to yield signs of hope happened here. Thailand was also the first Asian country to eliminate mother-to-child transmission of HIV. Now, Thailand has achieved the first part of UNAIDS’ 90-90-90 targets: 98 percent of people infected with HIV know their status.

Published
06 March 2019
From
Science Speaks
Mind the Gap: The Burden of HIV Among Racial and Ethnic Minority Groups and Their Participation in Preventive HIV Vaccine Clinical Trials

An analysis conducted by the HIV Vaccine Trials Network (HVTN) observed an overall increase in the proportion of racial and ethnic minorities enrolled in Phase 1 and Phase 2A preventive HIV vaccine clinical trials in the United States between 2002 and 2016 compared to 1988 to 2002. The findings were published on December 5, 2018 in Public Health Reports.

Published
16 February 2019
From
HIV Vaccine Trials Network
← First12345...29Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.